Gelonghui, March 15 | An investor asked Leadman (300289.SZ) on the investor interactive platform, “Please ask if your company has drugs with independent intellectual property rights developed through technical means such as chemical synthesis, genetic engineering, and antibody engineering.” The company replied that the company's current business focuses on the in vitro diagnosis industry and does not involve drugs.
利德曼(300289.SZ)：现有业务聚焦体外诊断行业，不涉及药物
Leadman (300289.SZ): The current business focuses on the in vitro diagnosis industry and does not involve drugs
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.